Sizing up the commercial and therapeutic prospects for the psychedelic revival

While hucksters and quacks try cash in on the crisis, the coronavirus is fast becoming a windfall for those already on top.

Competition among private medical interests is impeding the race for the cure.

Some of America's biggest companies are middlemen who profit from the system's wastefulness.

BioCorRx facilitated an anti-opioid implantation in an incarcerated person earlier this year. But the procedure hadn’t been approved by the FDA.

Big Pharma has a long and checkered history deploying racist and xenophobic tropes to protect their profits.

The rich fund museums to launder their reputations. Museums exploit identity politics to distract from the shady money funding them. In the art world, it’s all just business as usual.

Alaska’s health clinics were founded to help indigenous people like my family. Thanks to the FDA and Big Pharma, the clinics unwittingly enabled a crisis instead.

The controversial proposed deal with Purdue Pharma hints at better alternatives to for-profit pharmaceutical companies.

New documents show that Big Pharma isn’t the only culprit when it comes to getting people hooked on addictive drugs.

With a few breakout moments and a deft soundbite or two, the two senators stepped out of Elizabeth Warren's shadow.

Or are they just looking to cut a deal for the sake of cutting a deal?

The 2020 hopeful connected the dots between drug addiction and corporate greed, and "Trump country" took notice.

People are dying because they can't afford necessary medications, but drug manufacturers say they need high prices to fund future breakthroughs.

The House of Representatives' first oversight hearing of 2019 wasn't about Trump. It was about skyrocketing drug prices.

The industry's price-gouging economic model was engineered by Wall Street and its political enablers—and only Washington can fix it.

The rising star seemed destined to be a 2020 contender. But the populist wave and Trump resistance threaten to stall his ascent.